Sym004治疗抗EGFR耐药转移性结直肠癌的2期随机试验
这项多中心2期随机试验将254例抗EGFR治疗获得性耐药的转移性结直肠癌患者按1:1:1分为Sym004 12 mg/kg/wk组、Sym004 9 mg/kg负荷后6 mg/kg/wk组和研究者选择组。结果显示,在未选择人群中Sym004未改善总生存(A组对比C组HR 1.31,95%CI 0.92-1.87;B组对比C组HR 0.97,95%CI 0.68-1.40),但ctDNA定义的RAS/BRAF/EGFR ECD突变阴性亚组在B组中位OS为12.8个月,优于C组的7.3个月。
要点
- 未选择人群中Sym004未改善抗EGFR耐药mCRC的总生存。
- ctDNA显示抗EGFR治疗后瘤内基因组异质性高。
- ctDNA定义的RAS/BRAF/EGFR ECD突变阴性亚组可能获益,需前瞻性验证。
核心结论
- Sym004在未选择的抗EGFR获得性耐药mCRC人群中未改善总生存。
- ctDNA分子定义的亚组中Sym004疗效值得前瞻性临床验证。
研究设计与样本
- 多中心、2期、随机临床试验,2014年3月6日至2015年10月15日开展。
- 254例KRAS第2外显子野生型、标准化疗失败且抗EGFR单抗获得性耐药的mCRC患者纳入意向治疗人群。
- 患者按1:1:1随机分入Sym004 12 mg/kg/wk组、Sym004 9 mg/kg负荷后6 mg/kg/wk组或研究者选择治疗组。
- 分析循环肿瘤DNA用于生物标志物检测并追踪治疗期间克隆演化。
主要发现
- 意向治疗人群中位OS:A组7.9个月(95%CI 6.5-9.9),B组10.3个月(95%CI 9.0-12.9),C组9.6个月(95%CI 8.3-12.2)。
- A组对比C组HR 1.31(95%CI 0.92-1.87),B组对比C组HR 0.97(95%CI 0.68-1.40)。
- ctDNA显示抗EGFR治疗后患者瘤内基因组异质性高。
- Sym004有效靶向EGFR ECD突变癌细胞,Sym004治疗患者EGFR ECD ctDNA下降,但未转化为EGFR ECD突变患者的临床获益,可能与共存耐药机制有关。
- ctDNA定义(RAS/BRAF/EGFR ECD突变阴性)亚组中,B组中位OS 12.8个月,C组7.3个月。
关键数值与推荐
- 意向治疗人群254例,中位年龄63岁(范围34-91岁),男性63%。
- 主要终点为总生存,次要终点包括预设的ctDNA探索性生物标志物分析。
临床怎么用
- 抗EGFR耐药mCRC未选择人群不应常规使用Sym004。
- 可考虑以ctDNA检测RAS/BRAF/EGFR ECD突变状态筛选潜在获益人群,但须在临床试验框架内进行。
局限性
- Sym004在未选择人群中未显示总生存获益。
- EGFR ECD突变患者中ctDNA下降未转化为临床获益,可能与共存耐药机制有关。
- ctDNA分子定义亚组的获益为探索性分析,尚需前瞻性临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some anti-EGFR-refractory patients retain tumor EGFR dependency potentially targetable by agents such as Sym004, which is a mixture of 2 nonoverlapping monoclonal antibodies targeting EGFR. OBJECTIVE: To determine if continuous blockade of EGFR by Sym004 has survival benefit. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, phase 2, randomized, clinical trial comparing 2 regimens of Sym004 with investigator's choice from March 6, 2014, through October 15, 2015. Circulating tumor DNA (ctDNA) was analyzed for biomarker and tracking clonal dynamics during treatment. Participants had wild-type KRAS exon 2 mCRC refractory to standard chemotherapy and acquired resistance to anti-EGFR monoclonal antibodies. INTERVENTIONS: Participants were randomly assigned in a 1:1:1 ratio to Sym004, 12 mg/kg/wk (arm A), Sym004, 9 mg/kg loading dose followed by 6 mg/kg/wk (arm B), or investigator's choice of treatment (arm C). MAIN OUTCOMES AND MEASURES: Overall survival (OS). Secondary end points included preplanned exploratory biomarker analysis in ctDNA. RESULTS: A total of 254 patients were randomized (intent-to-treat [ITT] population) (median age, 63 [range, 34-91] years; 63% male; n = 160). Median OS in the ITT population was 7.9 months (95% CI, 6.5-9.9 months), 10.3 months (95% CI, 9.0-12.9 months), and 9.6 months (95% CI, 8.3-12.2 months) for arms A, B, and C, respectively (hazard ratio [HR], 1.31; 95% CI, 0.92-1.87 for A vs C; and HR, 0.97; 95% CI, 0.68-1.40 for B vs C). The ctDNA revealed high intrapatient genomic heterogeneity following anti-EGFR therapy. Sym004 effectively targeted EGFR ECD-mutated cancer cells, and a decrease in EGFR ECD ctDNA occurred in Sym004-treated patients. However, this did not translate into clinical benefit in patients with EGFR ECD mutations, likely owing to co-occurring resistance mechanisms. A subgroup of patients was defined by ctDNA (RAS/BRAF/EGFR ECD-mutation negative) associated with improved OS in Sym004-treated patients in arm B compared with arm C (median OS, 12.8 and 7.3 months, respectively). CONCLUSIONS AND RELEVANCE: Sym004 did not improve OS in an unselected population of patients with mCRC and acquired anti-EGFR resistance. A prospective clinical validation of Sym004 efficacy in a ctDNA molecularly defined subgroup of patients with refractory mCRC is warranted. TRIAL REGISTRATION: clinicaltrialsregister.eu Identifier: 2013-003829-29.
引用
- Montagut C, Argilés G, Ciardiello F, et al. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29423521. doi:10.1001/jamaoncol.2017.5245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。